

Date: 24 January 2019

Healthcare Professional Communication

Update regarding a prolonged out-of-stock situation affecting packs of Adalat® LA (Nifedipine)

Dear Healthcare Professional.

Further to the letter from Bayer in October 2018 regarding the supply of Adalat, we are writing to update you on the status of the Adalat LA supply interruption.

There continues to be an interruption to the supply of **Adalat LA 20mg, 30mg and 60mg prolonged-release tablets.** These packs will continue to be out-of-stock with resupply to the UK market expected in 2021.

The supply interruption is due to reduced manufacturing capacity as a result of ongoing significant remediation and modernisation activities at our Supply Centre in Leverkusen, Germany. The measures taken are to ensure a sustainable product supply in the future.

This reduced manufacturing capacity has, unfortunately, resulted in stock-out situations affecting our customers and patients, which we deeply regret. Bayer sincerely apologises for any inconvenience this supply interruption causes.

The competent authorities have been informed of the situation.

For product information enquiries please contact our Medical Information team on 0118 206 3116 or by email at medical.information@bayer.co.uk.

For supply information enquiries please contact our Customer Service team on 0118 206 3920.

Healthcare professionals may wish to consult https://www.medicines.org.uk/emc for details of alternative nifedipine products, whilst the decision to prescribe such alternatives remains at the prescriber's discretion.

Yours Sincerely,

Electronically signed

Tom Ellis

Women's Health & Established Products Business Manager

Bayer Plc

400 South Oak Way Reading Berks RG2 6AD United Kingdom Tel. +44 118 206 3116 Email.

Medical.information@bayer.co.uk

Bayer Plc is registered In England No. 935048 Registered office: 400 South Oak Way Reading RG2 6AD United Kingdom

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

Adverse events should also be reported to Bayer plc. Tel.: 0118 2063500, Fax.: 0118 2063703, Email: pvuk@bayer.com